Sorafenib is a RAF inhibitor approved for many malignancies, including hepatocellular carcinoma (HCC). cytotoxic Compact disc8+ T cells. These results led to a profound hold off in tumor development. Therefore, this nano-delivery technique to selectively focus on tumors and stop the paradoxical ERK activation could raise the feasibility of dual RAF/MEK inhibition to conquer sorafenib… Continue reading Sorafenib is a RAF inhibitor approved for many malignancies, including hepatocellular